Cohort characteristics (n = 107)
| . | N . | % . |
|---|---|---|
| Median age at diagnosis (range), y | 56 (34-79) | |
| Median follow-up, y | 9.3 | |
| Median survival, y | 15.7 | |
| Median time from diagnosis to blood collection, y | 2.7 | |
| Treated during follow-up | 76 | 71.0 |
| Male/female | 69/38 | 64/36 |
| Rai stage at sampling | ||
| 0 | 12 | 11.2 |
| I | 1 | 0.9 |
| II | 56 | 52.3 |
| III-IV | 20 | 18.7 |
| Not determined | 18 | |
| IGHV/ZAP-70/CD38 status | ||
| unmut IGHV/mut IGHV | 47/60 | (44/56) |
| ZAP-70+/ZAP-70− | 47/60 | (44/56) |
| CD38+/CD38− | 30/77 | (28/72) |
| Hierarchical cytogenetics (fluorescence in situ hybridization) | ||
| del 17p13 | 8 | 7.5 |
| del 11q23 | 9 | 8.4 |
| del 13q14 | 33 | 30.8 |
| Trisomy 12 | 4 | 3.7 |
| Normal karyotype | 16 | 15.0 |
| Not determined | 37 |
| . | N . | % . |
|---|---|---|
| Median age at diagnosis (range), y | 56 (34-79) | |
| Median follow-up, y | 9.3 | |
| Median survival, y | 15.7 | |
| Median time from diagnosis to blood collection, y | 2.7 | |
| Treated during follow-up | 76 | 71.0 |
| Male/female | 69/38 | 64/36 |
| Rai stage at sampling | ||
| 0 | 12 | 11.2 |
| I | 1 | 0.9 |
| II | 56 | 52.3 |
| III-IV | 20 | 18.7 |
| Not determined | 18 | |
| IGHV/ZAP-70/CD38 status | ||
| unmut IGHV/mut IGHV | 47/60 | (44/56) |
| ZAP-70+/ZAP-70− | 47/60 | (44/56) |
| CD38+/CD38− | 30/77 | (28/72) |
| Hierarchical cytogenetics (fluorescence in situ hybridization) | ||
| del 17p13 | 8 | 7.5 |
| del 11q23 | 9 | 8.4 |
| del 13q14 | 33 | 30.8 |
| Trisomy 12 | 4 | 3.7 |
| Normal karyotype | 16 | 15.0 |
| Not determined | 37 |
mut, mutated; unmut, unmutated; y, years.